PDS Biotechnology Debt 2025

PDS Biotechnology Aktienanalyse

What does PDS Biotechnology do?

PDS Biotechnology Corporation is a biopharmaceutical company founded in 2005. It is based in New Jersey, USA and employs around 35 employees. The company specializes in the development of drugs and therapies for the treatment of cancer and infectious diseases. PDS Biotechnology's business model is based on the use of a technology platform called Versamune®. This platform allows for the embedding of immunomodulatory agents in vaccines and cancer therapies. The goal is to activate and strengthen the body's immune defense against cancer and infections. PDS has four different divisions: cancer immunotherapies, infectious diseases, vetmedica, and research services. PDS's cancer immunotherapies focus on stimulating the immune system to help the body recognize and fight cancer cells. The Versamune® technology is used in combination with peptide-based vaccines. Versamune® is intended to help generate a strong and sustained immune response. The most advanced projects in cancer immunotherapy include PD1 vaccines and the PD1 vaccine combination program. PDS is also working on the development of Versamune®-based treatment options in the areas of infectious diseases and vetmedica. Advanced platform technologies have been developed based on the use of Versamune® and choice peptide fusion proteins. In the field of research services, PDS offers a range of services related to its technology platform. These include the manufacturing of Versamune® products, preclinical studies, as well as analysis and consulting. One of PDS's projects, currently being tested in clinical phase IIa, is a vaccine against human papillomavirus (HPV). HPV is a virus that plays a significant role in the development of various types of cancer, such as cervical cancer. The vaccine aims to strengthen the immune system against HPV and thereby reduce the risk of developing cancer. In addition to developing new drugs, PDS has also focused on improving existing treatment options. The company collaborates closely with research institutions and other companies to leverage new insights and technologies in order to develop better therapies. PDS Biotechnology is an emerging company with promising products and a strong commitment to developing groundbreaking therapies for the treatment of cancer and infectious diseases. Through the use of its Versamune® technology and expertise in immunotherapy, the company has the potential to change the future of medicine and improve the lives of millions of people. PDS Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding PDS Biotechnology's Debt Structure

PDS Biotechnology's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing PDS Biotechnology's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to PDS Biotechnology’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in PDS Biotechnology’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about PDS Biotechnology stock

What is the debt of PDS Biotechnology this year?

PDS Biotechnology has a debt level of -19.86 USD this year.

What was the debt of PDS Biotechnology compared to the previous year?

The debt of PDS Biotechnology has increased by -39.28% compared to the previous year dropped.

What are the consequences of high debt for investors in PDS Biotechnology?

High debt can pose a risk for investors of PDS Biotechnology, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of PDS Biotechnology?

Low debt means that PDS Biotechnology has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from PDS Biotechnology affect the company?

An increase in debt of PDS Biotechnology can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of PDS Biotechnology affect the company?

A reduction in debt of PDS Biotechnology can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of PDS Biotechnology?

Some factors that can influence the debt of PDS Biotechnology include investments, acquisitions, operating costs, and revenue development.

Why are the debts of PDS Biotechnology so important for investors?

The debts of PDS Biotechnology are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can PDS Biotechnology take to change the debt?

To change the debt, PDS Biotechnology can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does PDS Biotechnology pay?

Over the past 12 months, PDS Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PDS Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of PDS Biotechnology?

The current dividend yield of PDS Biotechnology is .

When does PDS Biotechnology pay dividends?

PDS Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PDS Biotechnology?

PDS Biotechnology paid dividends every year for the past 0 years.

What is the dividend of PDS Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PDS Biotechnology located?

PDS Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von PDS Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PDS Biotechnology from 10/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2025.

When did PDS Biotechnology pay the last dividend?

The last dividend was paid out on 10/12/2025.

What was the dividend of PDS Biotechnology in the year 2024?

In the year 2024, PDS Biotechnology distributed 0 USD as dividends.

In which currency does PDS Biotechnology pay out the dividend?

The dividends of PDS Biotechnology are distributed in USD.